

IN THE SUPREME COURT OF THE STATE OF MONTANA
No. DA 23-0572

SCARLET VAN GARDEREN, et al.,

Plaintiffs and Appellees,

v.

STATE OF MONTANA, et al.

Defendants and Appellants.

**BRIEF OF *AMICI CURIAE* BIOMEDICAL ETHICS AND PUBLIC
HEALTH SCHOLARS IN SUPPORT OF PLAINTIFFS/APPELLEES**

On appeal from the Montana Fourth Judicial District Court, Missoula County
Cause No. DV 2023–541, the Honorable Jason Marks, Presiding

APPEARANCES:

Michelle T. Weinberg
MICHELLE T. WEINBERG, PLLC
P.O. Box 1417
Missoula, MT 59801
(406) 314-3583
michelle@michelleweinberglaw.com

Katelyn Kang* (NY 5745799)
Valeria M. Pelet del Toro* (NY 5764667)
COOLEY LLP
55 Hudson Yards
New York, NY 10001
(212) 479-6000
kkang@cooley.com
vpeletdeltoro@cooley.com

Attorneys for Amici Curiae

**Admitted pro hac vice*

Austin Knudsen
Montana Attorney General

Thane Johnson
Michael D. Russel
Alwyn Lansing
Michael Noonan

Assistant Attorneys General
MONTANA DEPARTMENT OF
JUSTICE

P.O. Box 201401
Helena, MT 59620-1401
(406) 444-2026
thane.johnson@mt.gov
michael.russell@mt.gov
alwyn.lansing@mt.gov
michael.noonan@mt.gov

Emily Jones
Special Assistant Attorney General

JONES LAW FIRM, PLLC
115 N. Broadway Suite 410
Billings, MT 59101
(406) 384-7990
emily@joneslawmt.com

Attorneys for Defendants/Appellants

Alex Rate
Marthe Y. VanSickle
Akilah Deernose
ACLU OF MONTANA
P.O. Box 1968
Missoula, MT 59806
(406) 203-3375
deernosea@aclumontana.org
ratea@aclumontana.org

Malito Picasso*
Arijeet Sensharma*
ACLU FOUNDATION
125 Broadway Street
New York, NY 10004
(212) 549-2561
mpicasso@aclu.org
asensharma@aclu.org

Elizabeth O. Gill*
ACLU FOUNDATION
39 Drumm Street
San Francisco, CA 94109
(415) 343-1237
egill@aclunc.org

Matthew P. Gordon
Heather Shook*
Courtney Schirr*
Sara Cloon*
Kayla Lindgren*
PERKINS COIE, LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101
(206) 359-8000
mgordon@perkinscoie.com

Peter C. Renn*
Kell Olson*
LAMBDA LEGAL DEFENSE AND
EDUCATION FUND
800 S. Figueroa Street, Suite 1260
Los Angeles, CA 90017
(213) 382-7600
prens@lambdalegal.org
kolson@lambdalegal.org

Nora Huppert*
LAMBDA LEGAL DEFENSE
AND EDUCATION FUND
65 E. Wacker Place, Suite 2000
Chicago, IL 60601
(312) 663-4413
nhuppert@lambdalegal.org

Attorneys for Plaintiffs/Appellees
**Admitted pro hac vice*

TABLE OF CONTENTS

	Page(s)
TABLE OF CONTENTS.....	i
TABLE OF AUTHORITIES	ii
STATEMENT OF INTEREST OF <i>AMICI CURIAE</i>	1
STATEMENT OF THE ISSUES.....	2
SUMMARY OF THE ARGUMENT	3
ARGUMENT	5
I. GENDER-AFFIRMING CARE TO TREAT GENDER DYSPHORIA IS SUPPORTED BY A SUBSTANTIAL BODY OF EVIDENCE THAT DOES NOT JUSTIFY SINGLING IT OUT FOR DIFFERENTIAL TREATMENT.....	5
II. THE BAN CONTRAVENES KEY TENETS OF BIOMEDICAL ETHICS.	16
A. The Ban Forces Providers to Disregard Patients’ Autonomy.....	17
B. The Ban Forces Providers to Violate Their Duty of Beneficence.	21
C. The Ban Forces Providers to Violate Their Duty of Justice.	23
CONCLUSION.....	25

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>Brandt v. Rutledge</i> , 47 F.4th 661 (8th Cir. 2022)	10, 23
<i>Brandt v. Rutledge</i> , 551 F. Supp. 3d 882 (E.D. Ark. 2021)	23
<i>Buckman Co. v. Pls.’ Legal Comm.</i> , 531 U.S. 341 (2001).....	14
<i>Eknes-Tucker v. Governor of Alabama</i> , 80 F.4th 1205 (11th Cir. 2023)	7, 15
<i>Hastie v. Alpine Orthopedics & Sports Med.</i> , 382 Mont. 21 (2015)	17
<i>L.W. v. Skrmetti</i> , 83 F.4th 460 (6th Cir. 2023)	15, 16
<i>Planned Parenthood Cincinnati Region v. Taft</i> , 444 F.3d 502 (6th Cir. 2006)	12
Statutes	
S. 99, 2023 Leg., 68th Sess., Reg. Sess. § 4 (Mont. 2023).....	<i>passim</i>
S. 422, 2023 Leg., 68th Sess. (Mont. 2023)	14, 17
Other Authorities	
Am. Cancer Soc’y, <i>Late Effects of Childhood Cancer Treatment</i> (Sept. 18, 2017).....	20
Am. Cancer Soc’y, <i>Off-Label Drug Use</i> (Mar. 17, 2015)	13
Am. Med. Ass’n, <i>Code of Medical Ethics Opinion 1.1.1, Patient-Physician Relationships</i>	22
Am. Med. Ass’n, <i>Code of Medical Ethics Opinion 2.1.1, Informed Consent</i>	20

Am. Med. Ass’n, <i>Code of Medical Ethics Opinion 2.2.1, Pediatric Decision Making</i>	18, 19
Am. Soc’y of Clinical Oncology, <i>Recent Developments in Medicare Coverage of Off-Label Cancer Therapies</i> , 5 <i>J. Oncology Practice</i> (2009).....	14
Anthony J. Hatswell et al., <i>Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014</i> , <i>BMJ Open</i> (June 30, 2016)	12
Ayden I. Scheim et al., <i>Health and Health Care Among Transgender Adults in the United States</i> , 43 <i>Annual Rev. of Pub. Health</i> 503 (2021).....	5
Benjamin Freedman, <i>Equipoise and the Ethics of Clinical Research</i> , 317 <i>N. Engl. J. Med.</i> 141 (1987)	9
Beth A. Clark, <i>Ethics in Child & Youth Care Practice with Transgender Youth</i> , 8 <i>Int’l J. of Child, Youth & Fam. Studies</i> 74 (2017).....	19
Beth A. Clark & Alice Virani, <i>This Wasn’t a Split-Second Decision: An Empirical Ethical Analysis of Transgender Youth Capacity, Rights, and Authority to Consent to Hormone Therapy</i> , 18 <i>J. Bioethical Inquiry</i> 151 (2021)	19
Brendan J. Nolan et al., <i>Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization: A Randomized Clinical Trial</i> , <i>JAMA Network Open</i> (2023).....	9
Carla Pelusi et al., <i>Effects of Three Different Testosterone Formulations in Female-to-Male Transsexual Persons</i> , 11 <i>J. Sex Med.</i> 3002 (2014)	8
Christopher M. Wittich et al., <i>Ten common questions (and their answers) about off-label drug use</i> , 87 <i>Mayo Clinic Proc.</i> 982 (2012).....	16, 17
Cong. Rsch. Serv., <i>Off-Label Use of Prescription Drugs</i> (Feb. 23, 2021)	13

Denise Thomson et al., <i>Controlled Trials in Children: Quantity, methodological quality and descriptive characteristics of Pediatric Controlled Trials published 1948-2006</i> , 5 PLoS One (2010)	8
Edward L. Hannan, <i>Randomized Clinical Trials and Observational Studies: Guidelines for Assessing Respective Strengths and Limitations</i> , 1(3) JACC: Cardiovascular Interventions 211 (2008)	7
Gert Helgesson, <i>Children, Longitudinal Studies, and Informed Consent</i> , 8 Med., Health Care & Philos. 307 (2005).....	10
<i>Good medical practice: Duties of a doctor registered with the General Medical Council</i> , Gen. Med. Council (2001)	22
H. Christine Allen et al., <i>Off-Label Medication Use in Children, More Common Than We Think: A Systematic Review of the Literature</i> , 111 J. Okla State Med. Assoc. 776 (2018)	14, 15
Holger Schünemann et al. (eds.), <i>Grading of Recommend., Assess., Dev. & Eval. Handbook</i> 14 (2013)	11
Howard Balshem et al., <i>GRADE guidelines: 3. Rating the quality of evidence</i> , 64(4) J. Clinical Epidemiol. 401 (2011).....	11, 12
J. R. Vevaina et al., <i>Issues in biomedical ethics</i> , 39 Disease-a-Month 869 (1993).....	1
Jack L. Turban et al., <i>Access to gender-affirming hormones during adolescence and mental health outcomes among transgender adults</i> , 17(1) PLoS ONE 2 (2022)	10
James M. Beck & Elizabeth D. Azari, <i>FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions</i> , 53 Food & Drug L.J. 71 (1998)	15
Jessica Kremen et al., <i>Addressing Legislation That Restrict Access to Care for Transgender Youth</i> , 147 Pediatric Perspectives (2021).....	19
José A. Sacristán, <i>Clinical Research and Medical Care: Towards Effective and Complete Integration</i> , 15 BMC Med. Res. Methodol. (2015)	6

Katrien Oude Rengerink et al., <i>Pregnant women’s concerns when invited to a randomized trial: A qualitative case control study</i> , 15 BMC Pregnancy and Childbirth 207 (2015).....	8
Kellan Baker, <i>The Future of Transgender Coverage</i> , 376 New Eng. J. Med. 19, 1801-04 (May 2017).....	5
Kristina R. Olson et al., <i>Mental health of transgender children who are supported in their identities</i> , Pediatric Collections: LGBTQ+: Support and Care (2016).....	22
Lois Snyder Sulmasy & Thomas A. Bledsoe, <i>American College of Physicians Ethics Manual</i> 170, Annals of Internal Medicine 86 (7th ed. 2019).....	18
Meredithe McNamara et al., <i>A Critical Review of the June 2022 Florida Medicaid Report on the Medical Treatment of Gender Dysphoria</i> , Yale Sch. of Med. 1 (2022).....	11, 12
Natalie S. Blencowe et al., <i>Interventions in randomized controlled trials in surgery: issues to consider during trial design</i> , 16 Trials (2015).....	8
Norman P. Spack et al., <i>Children and adolescents with gender identity disorder referred to a pediatric medical center</i> , 129 Pediatrics (2012).....	22
Parth Shah et al., <i>Informed Consent</i> (2021).....	18
Phillip E. Wagner et al., 39.1 <i>Health (Trans)gressions: Identity and Stigma Management in Trans* Healthcare Support Seeking</i> 51 (Oct. 2016).....	24
Tom L. Beauchamp & James F. Childress, <i>Principles of Biomedical Ethics</i> (8th ed. 2019).....	<i>passim</i>
U.S. Food & Drug Admin., <i>Clinical Research Versus Medical Treatment</i> (Mar. 22, 2018).....	6
U.S. Food & Drug Admin., <i>The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective</i> (Nov. 24, 2017)	13

William Janssen, *A Historical Perspective on Off-Label Medicine:
From Regulation, Promotion, and the First Amendment to the Next
Frontiers*, SSRN Elec. J. (2014).....15

World Medical Association, *Declaration of Geneva* (1948).....21, 22

STATEMENT OF INTEREST OF *AMICI CURIAE*

Amici curiae listed in the Appendix are professors of law, medicine, and public health who teach and write about biomedical ethics and health-related rights and discrimination. Biomedical ethics, sometimes referred to as bioethics, is “the discipline of ethics dealing with moral problems arising in the practice of medicine and the pursuit of biomedical research.” J. R. Vevarina et al., *Issues in biomedical ethics*, 39 *Disease-a-Month* 869 (1993), <https://pubmed.ncbi.nlm.nih.gov/8243220>. *Amici* have a strong interest in ensuring that principles of biomedical ethics are accurately described and properly applied. They submit this brief to explain how Montana Senate Bill 99, effective on October 1, 2023, is inconsistent with foundational principles of biomedical ethics.

STATEMENT OF THE ISSUES

Whether the District Court correctly enjoined Defendants/Appellants from enforcing Montana Senate Bill 99 (S. 99, 2023 Leg., 68th Sess., Reg. Sess. § 4 (Mont. 2023)).

SUMMARY OF THE ARGUMENT

From flu shots to cancer treatments, medical providers regularly support patients (and their parents, when the patients are minors) in deciding whether a given medical treatment is necessary and appropriate for them, without any undue interference from the State.

The Montana law at issue in this appeal, Senate Bill 99, S. 99, 2023 Leg., 68th Sess., Reg. Sess. § 4 (Mont. 2023) (the “Ban”), upends that normal operation of medical practice for a specific, targeted group of patients: transgender minors seeking gender-affirming medical care for gender dysphoria. The Ban outlaws the normal course of medical decision-making for these individuals, under which a patient, their parents, and their medical providers carefully deliberate to make an informed, individualized decision about whether gender-affirming care is medically appropriate and in the best interest of the particular patient. The State imposed this sweeping Ban even though every major medical organization in the United States has concluded that gender-affirming care, including for minors, is not only safe and effective, but is the *only* evidence-based treatment for gender dysphoria.

Categorically barring patients from accessing evidence-based treatment is irreconcilable with foundational precepts of biomedical ethics, particularly where, as here, that treatment is the *only* evidence-based treatment available for a given medical need and the prohibition applies *only* to a group of patients singled out

because of their identity.

As explained further below, core principles of biomedical ethics include respect for autonomy, beneficence, and justice. The Ban deprives transgender patients of their ability to receive medically necessary and appropriate treatment to which they have given informed consent (autonomy). It forces providers to deny their patients care that is known to alleviate suffering, and thus to abandon their patients to serious physical and mental harm (beneficence). And it compels providers to deny care that only patients who are transgender need, thereby exacerbating stigma and inequity and damaging trust in the medical profession (justice).

Montana tries to justify these harms by suggesting that gender-affirming care lacks a sound evidentiary base. That position is unfounded and badly misunderstands how medical knowledge is credibly generated. The gender-affirming care prohibited by the Ban has been developed through rigorous and appropriate methods and rests on a strong evidentiary basis.

In sum, the Ban singles out and effectively bans gender-affirming care for transgender patients based on false notions of science, public health, and biomedical ethics, without considering the grave harm that will come from denying vulnerable patients critical health care. This Court should affirm the District Court's order.

ARGUMENT

I. GENDER-AFFIRMING CARE TO TREAT GENDER DYSPHORIA IS SUPPORTED BY A SUBSTANTIAL BODY OF EVIDENCE THAT DOES NOT JUSTIFY SINGLING IT OUT FOR DIFFERENTIAL TREATMENT.

The gender-affirming care prohibited by the Ban was developed through rigorous and appropriate methods and is recommended by every major medical association in the United States. Kellan Baker, *The Future of Transgender Coverage*, 376 *New Eng. J. Med.* 19, 1801–04 (May 2017); Ayden I. Scheim et al., *Health and Health Care Among Transgender Adults in the United States*, 43 *Annual Rev. of Pub. Health* 503, 510 (2021). Nonetheless, the State characterizes gender-affirming care as “experimental” and questionable treatment that has not been sufficiently vetted. *See* Appellants’ Br. 1, 6, 8, 11, 16, 20, 22, 31, 36, 45 n.13, 46, 48, 51. Likewise, the State emphasizes that using puberty blockers and hormone therapy to treat gender dysphoria is not approved by the U.S. Food and Drug Administration (the “FDA”), suggesting that the FDA’s silence on this particular use implies that the care is experimental or harmful. *Id.* at 8, 47–48.

These claims about gender-affirming care are wrong. As the District Court found, the medical care targeted by the Ban is supported by a strong evidentiary base. Order Granting Pls.’ Mot. for Prelim. Inj. (“Order”) at 30–32, 43. The State’s attempts to justify the Ban reflect a fundamental misunderstanding of medical practice and the ways medical knowledge and treatment guidelines are generated,

particularly in the context of pediatric care. The medical care targeted by the Ban is based on appropriate, ethical study and medical knowledge—it is not “experimental.”

To start, the State conflates clinical care with clinical research and fails to engage with the ethical standards attendant to each. Medical care delivered by a clinician to a patient and clinical research have distinct purposes and processes. *See, e.g.,* FDA, *Clinical Research Versus Medical Treatment* (Mar. 22, 2018), <https://www.fda.gov/patients/clinical-trials-what-patients-need-know/clinical-research-versus-medical-treatment>. In the clinical care setting, the provider’s aim is to improve a patient’s health, and the provider is duty bound to act in that patient’s best interest. By contrast, the aim of a research study is to generate knowledge useful for *future* patients. *See* José A. Sacristán, *Clinical Research and Medical Care: Towards Effective and Complete Integration*, 15 BMC Med. Res. Methodol. (2015), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323129/>. A research study’s protocols must be ethically designed and administered, but there is no obligation to do what is in each participant’s best interest. Importantly, receiving gender-affirming care for gender dysphoria does not automatically render a patient a subject of a research study; gender-affirming medical care has been known to advance individual patients’ best interests and is provided as clinical care for that purpose. The use of the label “experimental” in this context is thus misleading.

Further, the State’s arguments misconceive how medical knowledge is credibly and rigorously generated, and so, among other things, wrongly suggest that the lack of randomized control trials, Appellants’ Br. 8, means the care has not been appropriately vetted. *See, e.g., Eknes-Tucker v. Governor of Alabama*, 80 F.4th 1205, 1217 (11th Cir. 2023) (citing witness emphasizing lack of randomized studies). But there is no one method used to generate medical knowledge in all contexts. Rather, medical knowledge and practice are informed by a range of research and clinical inputs that are often dependent on the type of care, context, and state of development.

A randomized control trial—where some participants are randomly assigned to a treatment group and others are randomly assigned to a control group—is one of many types of credible research designs used to evaluate a medical intervention. Medical interventions also can be and often are evaluated through observational studies, which include cross-sectional studies and longitudinal studies. *See, e.g., Edward L. Hannan, Randomized Clinical Trials and Observational Studies: Guidelines for Assessing Respective Strengths and Limitations*, 1(3) JACC: Cardiovascular Interventions 211–17 (2008), <https://www.sciencedirect.com/science/article/pii/S1936879808001702>. In addition, randomized *clinical* trials, which compare different established interventions to one another, may be used to inform medical treatment. For example,

a randomized clinical trial has been used to evaluate sex hormone treatment for gender dysphoria, comparing different, established pharmacological treatments to one another. See Carla Pelusi et al., *Effects of Three Different Testosterone Formulations in Female-to-Male Transsexual Persons*, 11 J. Sex Med. 3002–11 (2014), [https://www.jsm.jsexmed.org/article/S1743-6095\(15\)30626-3/fulltext](https://www.jsm.jsexmed.org/article/S1743-6095(15)30626-3/fulltext).

Study methods other than randomized control trials and extended longitudinal studies may be preferable in some circumstances, given that these are not always feasible, appropriate, or the most reliable way to evaluate a medical intervention. For instance, randomized control trials are rarely used for interventions focused on children or pregnant people, or for surgical interventions. See, e.g., Denise Thomson et al., *Controlled Trials in Children: Quantity, methodological quality and descriptive characteristics of Pediatric Controlled Trials published 1948–2006*, 5 PLoS One (2010), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948021/>; Katrien Oude Rengerink et al., *Pregnant women’s concerns when invited to a randomized trial: A qualitative case control study*, 15 BMC Pregnancy and Childbirth 207 (2015), <https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-015-0641-x>; Natalie S. Blencowe et al., *Interventions in randomized controlled trials in surgery: issues to consider during trial design*, 16 Trials (2015), <https://doi.org/10.1186/s13063-015-0918-4>. Randomized control trials also are only ethical when there is clinical “ equipoise,” which means they are

only appropriate when there is genuine uncertainty about whether the intervention will be more effective than the control. See Benjamin Freedman, *Equipoise and the Ethics of Clinical Research*, 317 N. Engl. J. Med. 141–45 (1987), <https://www.nejm.org/doi/full/10.1056/NEJM198707163170304>. That is because it is unethical to knowingly expose participants to an inferior intervention or control.

This principle plainly applies to the treatments for gender dysphoria subject to the Ban: performing randomized, placebo-controlled trials on the efficacy of that treatment would be unethical, because the prevailing view among the medical community based on the existing evidence is that for patients who need it, hormone therapy is superior to a lack of pharmacological treatment. See Brendan J. Nolan et al., *Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization: A Randomized Clinical Trial*, JAMA Network Open (2023), <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809058>.

The State’s critique of the lack of research regarding the “long-term” safety and efficacy of gender-affirming care is also wrong. Appellants’ Br. 8–9, 44 n.10. In reality, there are many long-term studies supporting the provision of gender-affirming care to treat gender dysphoria, including for minors.¹ Moreover, the

¹ See, e.g., Jack L. Turban et al., *Access to gender-affirming hormones during adolescence and mental health outcomes among transgender adults*, 17(1) PLoS

underlying premise of this argument—that long-term studies are necessary to prove a treatment’s efficacy and safety—is mistaken. Longitudinal studies need not last for some unspecified “long-term” period to be reliable, nor are such studies always the most ethically and legally appropriate. Often, other reliable and trustworthy methods are preferable. For example, before conducting longitudinal studies involving children, researchers must consider a child’s privacy and autonomy all while maintaining data integrity—a sometimes difficult balancing act that can be avoided by using an alternative study design. *See, e.g.,* Gert Helgesson, *Children, Longitudinal Studies, and Informed Consent*, 8 *Med., Health Care & Philos.* 307 (2005), <https://doi.org/10.1007/s11019-005-0978-4>.

The State also betrays its erroneous understanding of what it means for evidence to be graded as “low quality.” Appellants’ Br. 51. Under the GRADE system, which is often used for presenting summaries of scientific evidence and making clinical practice recommendations, the level of quality ascribed to evidence is based on the type of research methodology used—evidence generated via a randomized control trial is typically labeled “high quality” and evidence generated via an observational study is typically labeled “low quality.” Howard Balshem et al., *GRADE guidelines: 3. Rating the quality of evidence*, 64(4) *J. Clinical*

ONE 2 (2022), <https://doi.org/10.1371/journal.pone.0261039> (collecting studies); *see also Brandt v. Rutledge*, 47 F.4th 661, 671 (8th Cir. 2022).

Epidemiol. 401 (2011); Holger Schünemann et al. (eds.), *Grading of Recommend., Assess., Dev. & Eval. Handbook* 14 (2013) (“GRADE Handbook”). Randomized trials with limitations such as inconsistent results or publication bias will go down in quality, and observational studies with a dose-response gradient (relationship between a stimulus and a response) or large magnitude of effect will go up in quality. GRADE Handbook at 13.

These “high quality” and “low quality” labels under GRADE thus are descriptive of the underlying method, but they do not necessarily reflect the reliability of the evidence generated. As noted, observational studies are sometimes favored for both ethical and practical reasons. For example, despite their “low quality” technical category, observational studies have been used in forming the Cholesterol Guidelines of the American College of Cardiology and the American Heart Association. *See* Meredith McNamara et al., *A Critical Review of the June 2022 Florida Medicaid Report on the Medical Treatment of Gender Dysphoria*, Yale Sch. of Med. 1, 16 (2022). The same is true for a range of other treatments, from gallbladder surgery to the determination that aspirin is not appropriate to treat fevers in children. *See id.* at 14, 16. And with gender-affirming medical care to treat gender dysphoria, randomized control trials are not appropriate for the reasons described above. Because randomized control trials are often inappropriate or infeasible, research that falls in the technical category of “low quality” as that term is used in

the GRADE system can still be reliable and valuable when it comes to clinical practice. *See* McNamara at 15.

Rather, “low-quality” evidence may be and often is sufficient to justify a strong recommendation for clinical care under that same grading system. *See* GRADE Handbook at 5; Balshem at 402–04. Accordingly, the treatment for many other conditions, such as drugs for cancer and hematologic disorders, are widely recommended and used based on similarly “low-quality” evidence, without having been studied through randomized, controlled clinical trials. *See* Anthony J. Hatzwell et al., *Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014*, *BMJ Open* (June 30, 2016), <https://pubmed.ncbi.nlm.nih.gov/27363818/>.

Furthermore, and contrary to the claims of the State’s experts, a medication need not be approved by the FDA for a particular indication to be safe and effective for that indication. Off-label drug use is legal, accepted, and, when medically indicated, safe and in service of a patient’s best interest. *See Planned Parenthood Cincinnati Region v. Taft*, 444 F.3d 502, 505 (6th Cir. 2006).

An understanding of the FDA approval process makes clear why there is nothing unsafe or inappropriate about off-label use. Garnering the FDA’s approval of a drug requires showing that it is both safe—*i.e.*, the benefits outweigh the potential risks—and effective for its intended use. *See* FDA, *The FDA’s Drug*

Review Process: Ensuring Drugs Are Safe and Effective (Nov. 24, 2017), <https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective>. It is well-established practice that, once a drug has been approved by the FDA, health care providers may then prescribe it for other medically appropriate uses and in other dosages at their discretion without pharmaceutical companies first having to return to the FDA and seek approval for each indication. *See Taft*, 444 F.3d at 505. Such off-label use occurs because medical knowledge about how a drug might be beneficial in a different context or a different dosage continues to develop after FDA approval, but it is often too costly and impractical for drug makers to put each possible use of a drug through the FDA’s “formal, lengthy, and expensive” approval process. Am. Cancer Soc’y, *Off-Label Drug Use* (Mar. 17, 2015), <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/off-label-drug-use.html>. In addition, providers often prefer that drug makers *not* seek approval for every off-label use, given that it could increase the cost of the drug and limit the scope of its clinical application, all of which would make it less available to their patients. *See id.*; Cong. Rsch. Serv., *Off-Label Use of Prescription Drugs* 4 (Feb. 23, 2021), <https://sgp.fas.org/crs/misc/R45792.pdf>.

Off-label use is legal because FDA approval only limits how a drug can be marketed—*i.e.*, a drug cannot be marketed for a use different from its FDA-approved

use—but not how a physician can prescribe it. *See Buckman Co. v. Pls.’ Legal Comm.*, 531 U.S. 341, 351 & n.5 (2001).

In fact, multiple federal and state laws have been enacted in recent years to promote and protect off-label prescriptions. *See, e.g.*, S. 422, 2023 Leg., 68th Sess. (Mont. 2023) (allowing patients to take investigational drugs, biological products, or devices under Montana’s “Right to Try” law); Am. Soc’y of Clinical Oncology, *Recent Developments in Medicare Coverage of Off-Label Cancer Therapies*, 5 J. Oncology Practice 18–20 (2009), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790627/> (discussing 1993 legislation requiring Medicare to cover off-label uses of anti-cancer drugs and an expansion of Medicare’s off-label coverage in 2008).

Off-label use is especially common and important in treating minors. Minors are often excluded from clinical drug studies, including for ethical reasons. *See* Christopher M. Wittich et al., *Ten common questions (and their answers) about off-label drug use*, 87 Mayo Clinic Proc. 982 (2012) (citing study finding that nearly 80% of children discharged from pediatric hospitals were taking at least one off-label medication and discussing range of widely practiced off-label drug uses in pediatric population); H. Christine Allen et al., *Off-Label Medication Use in Children, More Common Than We Think: A Systematic Review of the Literature*, 111 J. Okla State Med. Assoc. 776–83 (2018),

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677268> (surveying ten years of literature and finding that “[t]he use of off-label medications in children remains a common practice for pediatric providers”).

Finally, and critically, off-label use is often essential for delivering the best care. James M. Beck & Elizabeth D. Azari, *FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions*, 53 Food & Drug L.J. 71–104 (1998), <https://pubmed.ncbi.nlm.nih.gov/11795338/>; William Janssen, *A Historical Perspective on Off-Label Medicine: From Regulation, Promotion, and the First Amendment to the Next Frontiers*, SSRN Elec. J. (2014), https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2519223.

Thus, off-label use is legal, common, and often essential for delivering medically necessary care. Any suggestion otherwise—including the Sixth Circuit’s contention, embraced by the Eleventh Circuit, that off-label use signals that “the FDA is not prepared to put its credibility and testing protocols behind the [drug’s] use,” *L.W. v. Skrmetti*, 83 F.4th 460, 478 (6th Cir. 2023); *see also Eknes-Tucker*, 80 F.4th at 1225 n.19—greatly misunderstands and misstates how the FDA works.

* * *

In sum, none of the State’s proclaimed “justification[s]” for the Ban hold up to scrutiny. Appellants’ Br. 46. Rather, the State’s arguments are based on a fundamental misunderstanding of both how scientific knowledge is generated and

the FDA approval process. Contrary to the State’s claims, the Ban does not prohibit treatment that is “experimental.” Indeed, were the State’s erroneous arguments an acceptable basis for banning medical care or excluding it from coverage, a significant portion of modern medical practice would be in jeopardy and unjustifiable harm would be inflicted on minors who are transgender.

II. THE BAN CONTRAVENES KEY TENETS OF BIOMEDICAL ETHICS.

The Ban eliminates a patient’s ability to make a decision, together with their medical providers and parents (where patient is a minor), about whether accessing a safe and effective form of treatment is in their best interest. As a result, the Ban is directly at odds with key tenets of biomedical ethics: respect for autonomy, beneficence, and justice. Tom L. Beauchamp & James F. Childress, *Principles of Biomedical Ethics*, 13 (8th ed. 2019). These universal principles, which are the cornerstones of modern-day healthcare standards, guide providers’ treatment decisions regardless of the type of medical care they are providing, and can provide “meaningful guidance” to courts assessing wholesale bans on and/or exclusions of insurance coverage for care. *Contra L.W.*, 83 F.4th at 478. To be clear, *amici* do not invoke these principles to suggest that they provide the legal test pursuant to which judges should “assess the validity of [the Ban].” *Id.* Rather, *amici* discuss how the Ban compromises these principles rather than protecting them. *Amici* have a strong interest in ensuring that courts and policymakers alike have an accurate

understanding of bioethics, and the discussion that follows accordingly explains why the Ban is irreconcilable with bioethical principles and therefore why any asserted interest in advancing bioethics should not be credited.

A. The Ban Forces Providers to Disregard Patients' Autonomy.

As a general matter, Montana has repeatedly acknowledged the importance of obtaining informed consent and respecting patient decision-making, reflecting the core biomedical ethical principle of respect for autonomy. That principle requires that patients have the ability to decide whether to receive appropriate medical care within the framework of informed consent. Beauchamp & Childress at 105. For example, in Montana, individuals can bring “medical malpractice claim[s] premised on a theory of lack of informed consent.” *Hastie v. Alpine Orthopedics & Sports Medicine*, 382 Mont. 21, 28 (2015) (citation omitted). Montana also has enacted a “Right to Try” law, which allows any patient, in consultation with their physician, to give “informed consent” to use non-FDA approved drugs and medical products. S. 422, 2023 Leg., 68th Sess. (Mont. 2023).

In stark contrast to these laws, the Ban attacks autonomy by preventing individuals from pursuing, and health care professionals from providing, beneficial medical treatment with due regard for a patient’s interests.

Empowering a patient’s autonomy is essential to the integrity of the provider-patient relationship, as well as the patient’s individual liberty and ability to

determine the course of their life. In keeping with that bioethical principle, “the physician’s professional role [is] to make recommendations on the basis of the best available medical evidence and to pursue options that comport with the patient’s unique health needs, values, and preferences.” Lois Snyder Sulmasy & Thomas A. Bledsoe, *American College of Physicians Ethics Manual* 170, *Annals of Internal Medicine* 86 (7th ed. 2019) (“ACP *Ethics Manual*”), <https://www.acpjournals.org/doi/10.7326/m18-2160>. Informed consent is a crucial mechanism for ensuring respect for autonomy. In all non-emergency encounters, the provider is obligated to offer the patient material information and guidance, but the patient must be trusted and empowered to make the informed and voluntary decision that best advances their interests. See Parth Shah et al., *Informed Consent* (2021), <https://www.ncbi.nlm.nih.gov/books/NBK430827/>. After the patient makes their decision, the provider’s duty is to “protect and foster [the] patient’s free, uncoerced choices.” *ACP Ethics Manual* at 74.

Where, as here, the patients at issue include minors, the informed consent process usually involves the provider, the minor patient, and the minor’s parents. When that is so, each actor has an important role to play: the provider offers medical instruction, the parents provide stewardship and consent, and the minor—assisted by that medical instruction and parental stewardship—provides assent. See Am. Med. Ass’n (“AMA”), *Code of Medical Ethics Opinion 2.2.1, Pediatric Decision*

Making, <https://www.ama-assn.org/delivering-care/ethics/pediatric-decision-making>; Beth A. Clark, *Ethics in Child & Youth Care Practice with Transgender Youth*, 8 Int'l J. of Child, Youth & Fam. Studies 74 (2017), <http://dx.doi.org/10.18357/ijcyfs82201716754>.

The process of informed consent (which, for minors, also frequently includes their parents) involves five core elements: 1) patient competence, 2) disclosure, 3) comprehension, 4) voluntariness, and 5) consent. Beauchamp & Childress at 122. As to the first element, parents generally have competence to participate in the informed consent process on behalf of their minor children, and many adolescent patients also have the competence to participate in the informed consent process, including in the context of gender-affirming care. See Jessica Kremen et al., *Addressing Legislation That Restrict Access to Care for Transgender Youth*, 147 *Pediatric Perspectives* (2021), <https://pubmed.ncbi.nlm.nih.gov/33883246/>; Beth A. Clark & Alice Virani, *This Wasn't a Split-Second Decision: An Empirical Ethical Analysis of Transgender Youth Capacity, Rights, and Authority to Consent to Hormone Therapy*, 18 *J. Bioethical Inquiry* 151–64 (2021), <https://pubmed.ncbi.nlm.nih.gov/33502682/>.

Once competence has been established, the elements of disclosure and comprehension require the provider to accurately and sensitively present relevant information about any diagnosis; the nature and purpose of recommended

interventions; the burdens, risks, and expected benefits of all options, including forgoing treatment; and any limitations to the medical community's knowledge regarding burdens, risks, and expected benefits. AMA, *Code of Medical Ethics Opinion 2.1.1, Informed Consent*, <https://www.ama-assn.org/delivering-care/ethics/informed-consent>.

For the fourth element, voluntariness, the provider must then assess the patient's ability to understand relevant medical information and the implications of treatment alternatives and to make an independent, voluntary decision. *Id.* Finally, the patient—and, where the patient is a minor, usually the parents as well—decides how to proceed.

From the perspective of biomedical ethics, a decision that is made by a patient through a process of informed consent and that aligns with a provider's recommendation should be fully respected. Indeed, medical professionals and patients are regularly entrusted to together decide the best course of treatment, including when the treatment has significant risks or permanent effects. Pediatric chemotherapy or radiation, for example, are subject to principles of informed consent, despite the potential lasting effects on growth development and reproductive capabilities. *See, e.g., Am. Cancer Soc'y, Late Effects of Childhood Cancer Treatment* (Sept. 18, 2017), <https://www.cancer.org/treatment/children-and-cancer/when-your-child-has-cancer/late-effects-of-cancer-treatment.html>. Pediatric

breast reduction performed to address excess breast tissue, back pain, or social anxiety; pediatric rhinoplasty; and orthopedic surgery on minors following sports injuries likewise can have enduring impacts. There is nothing unique about gender-affirming care that justifies banning this care or denying insurance coverage for it even though the provider, and the patient all agree about the best course of action.

By prohibiting health care providers from offering medically necessary and appropriate treatment to patients with gender dysphoria and denying patients the ability to access such care when they have given informed consent, the Ban disrespects autonomy and undermines the provider-patient relationship.

B. The Ban Forces Providers to Violate Their Duty of Beneficence.

The duty to act in the best interest of the patient is called beneficence, and is best understood as “a group of norms pertaining to relieving, lessening, or preventing harm and providing benefits and balancing benefits against risks and costs.” Beauchamp & Childress at 13; *see also id.* at 217. Medical professionals in the United States and around the world take oaths and are held to duties that encompass beneficence. The World Medical Association’s “Modern Hippocratic Oath” requires physicians to attest upon admission to the medical profession that the “health of [their] patient[s] will be [their] first consideration.” World Medical Association, *Declaration of Geneva* (1948). Likewise, the United Kingdom’s General Medical Council requires physicians to “make the care of your patient your

first concern.” *Good medical practice: Duties of a doctor registered with the General Medical Council*, Gen. Med. Council 70–78 (2001), <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-medical-practice/duties-of-a-doctor>. And the AMA recognizes that “[t]he practice of medicine, and its embodiment in the clinical encounter between a patient and a physician, is fundamentally a moral activity that arises from the imperative to care for patients and to alleviate suffering.” AMA, *Code of Medical Ethics Opinion 1.1.1, Patient-Physician Relationships*, <https://www.ama-assn.org/system/files/code-of-medical-ethics-chapter-1.pdf>.

Applying the principle of beneficence to the treatment of patients with gender dysphoria is straightforward. When untreated, gender dysphoria has serious mental and physical consequences, including anxiety, depression, self-harm, and suicidality. See, e.g., Norman P. Spack et al., *Children and adolescents with gender identity disorder referred to a pediatric medical center*, 129 *Pediatrics* (2012), <https://pubmed.ncbi.nlm.nih.gov/22351896>; Kristina R. Olson et al., *Mental health of transgender children who are supported in their identities*, *Pediatric Collections: LGBTQ+: Support and Care (Part 3: Caring for Transgender Children)* (2016) <https://publications.aap.org/pediatrics/articleabstract/137/3/e20153223/81409/Mental-Health-of-Transgender-Children-Who-Are>; Order at 41 (finding that “minors in Montana experiencing gender dysphoria . . . are at risk of facing severe

psychological distress if they are blocked from receiving [gender-affirming] care”). By contrast, evidence from both research and clinical experience makes clear that gender-affirming care improves patients’ health and alleviates their suffering. *See, e.g., Brandt*, 47 F.4th at 671; *Brandt v. Rutledge*, 551 F. Supp. 3d 882, 891 (E.D. Ark. 2021). In order to practice beneficence, practitioners must act for the benefit of the patient and promote their welfare. This is not possible when the State denies care to transgender patients.

In sum, the principle of beneficence obligates providers to remove conditions that will cause harm to others. *Beauchamp & Childress* at 219. By mandating that providers deny care to their patients with gender dysphoria when the patient seeks that care and the provider deems it medically indicated, the Ban forces providers to cause harm to their patients and, thus, to violate their core duty of beneficence.

C. The Ban Forces Providers to Violate Their Duty of Justice.

A third core principle of bioethics—justice—requires providers to acknowledge inequalities in the delivery of medical care and to work toward fair, equitable, and appropriate treatment for all. *Beauchamp & Childress* at 267–68; *Clark* at 79. The Ban undermines this ethical duty of providers by barring transgender individuals from receiving gender-affirming care. Specifically, the Ban denies care to a certain class of patients based on their transgender identity: care is banned only if is for treatment of gender dysphoria, which is care that only

transgender individuals seek.

For example, the Ban, if allowed to go into effect, may force individuals who are transgender to endure the negative health effects from stopping gender-affirming care and to fear for their ability to survive without treatment. *See* Order at 40–45. These potential costs are on top of the many socioeconomic and geographic barriers to gender-affirming care that transgender youth often already face. *See* Phillip E. Wagner et al., 39.1 *Health (Trans)gressions: Identity and Stigma Management in Trans* Healthcare Support Seeking* 51 (Oct. 2016). The Ban exacerbates and reinforces these already significant challenges by preventing transgender individuals from accessing the gender-affirming healthcare they require. In addition, being denied insurance coverage for gender-affirming care may lead transgender people to avoid seeking medical care altogether, or to choose between their health care, their food, their safety, or their housing.

Medical practitioners must not cause patients to fear seeking care, nor deny them care that, by definition, only people who are transgender need. The Ban forces health care providers to violate the core biomedical ethics principle of justice by mandating discrimination against a vulnerable and stigmatized population. By prohibiting minors who are transgender from accessing treatment for gender dysphoria simply because they are transgender, the Ban deprives them of their

autonomy and signals that they are not worthy of beneficence. Without autonomy and beneficence, only injustice can occur.

* * *

The Ban is unsupported by biomedical ethics or any of its core principles. To the contrary, the Ban commands their violation, for no legitimate purpose, resulting in physical and emotional suffering.

CONCLUSION

Unwarranted restrictions on the provision of health care by the State are unethical and detrimental to public health. The Ban contravenes multiple, fundamental principles of biomedical ethics and requires providers to harm their transgender patients. Were the State permitted to enforce the Ban, it would open the door to unprecedented State intrusion into medicine and patient rights. This Court should reject such a result and affirm the District Court's ruling.

Dated: April 9, 2024

Respectfully submitted,

/s/ Michelle T. Weinberg

Katelyn Kang* (NY 5745799)
Valeria M. Pelet del Toro* (NY 5764667)
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2103
Telephone: (212) 479-6000
kkang@cooley.com
vpeletdeltoro@cooley.com

Michelle T. Weinberg (42333158)
MICHELLE T WEINBERG, PLLC
P.O. Box 1417
Missoula, MT 59806-1417
Telephone: (406) 201-9520
michelle@whlawmt.com

Attorneys for Amici Curiae

**Admitted pro hac vice*

CERTIFICATE OF COMPLIANCE

Pursuant to Rule 11 of the Montana Rules of Appellate Procedure, I certify this brief is printed with a proportionately spaced Times New Roman typeface in 14-point font, is double spaced, and the word count calculated by the word processing software does not exceed 5,000 words, excluding the cover page, tables, and certificates.

Dated: April 9, 2024

/s/ Michelle T. Weinberg
Michelle T. Weinberg

APPENDIX

List of *Amici Curiae*

Amici include the following individuals, whose affiliations are provided for identification purposes only:

Elizabeth Rona Boskey

Instructor of Social and Behavioral Sciences
Harvard T.H. Chan School of Public Health

Khiara M. Bridges

Professor of Law
University of California, Berkeley School of Law

David S. Cohen

Professor of Law
Drexel University, Thomas R. Kline School of Law

Charlene Galarneau

Senior Lecturer, Department of Global Health and Social Medicine
Faculty Member, Center for Bioethics
Harvard Medical School

Joanna Grossman

Ellen K. Solender Endowed Chair in Women and the Law and Professor of Law
SMU Dedman School of Law

Lisa C. Ikemoto

Martin Luther King Jr. Professor of Law
University of California, Davis School of Law

Maya Manian

Professor of Law
American University Washington College of Law

Benjamin Mason Meier

Professor of Health Policy
The University of North Carolina at Chapel Hill

Michelle Oberman

Katharine and George Alexander Professor of Law
Santa Clara University School of Law

Dara Purvis

Professor of Law
Penn State Law

Nadia N. Sawicki

Georgia Reithal Professor of Law
Co-Director, Beazley Institute for Health Law & Policy
Loyola University Chicago School of Law

Michael R. Ulrich

Assistant Professor of Health Law, Ethics, & Human Rights
Boston University School of Public Health and School of Law

Ruqaiijah Yearby

Kara J. Trott Professor in Health Law
The Ohio State University, Moritz College of Law